00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
05:34 , Feb 8, 2019 |  BC Week In Review  |  Clinical News

Array reports updated Phase III OS data for triple combo mCRC therapy

Array BioPharma Inc. (NASDAQ:ARRY) reported updated data from the safety lead-in portion of the Phase III BEACON CRC trial showing that encorafenib (LGX818) plus binimetinib (MEK162) and Erbitux cetuximab led to a median overall survival...
23:18 , Feb 1, 2019 |  BioCentury  |  Product Development

Year of the lion

With three data readouts coming in 2019, Aslan Pharmaceuticals Ltd. is hoping this will be the year it starts to reap the benefits of its 2012 strategy rethink, giving the biotech more options for advancing...
05:09 , Jan 5, 2019 |  BioCentury  |  Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
04:21 , Jan 4, 2019 |  BC Week In Review  |  Financial News

Rakuten Aspyrian grows series C to $284M

Rakuten Aspyrian Inc. (San Diego, Calif.) raised $134 million led by CEO Hiroshi Mikitani in the second tranche of a $284 million series C round as the company conducts a Phase III trial of photoimmunotherapy...
00:30 , Dec 22, 2018 |  BC Extra  |  Financial News

Rakuten Aspyrian grows series C to $284M

Rakuten Aspyrian Inc. (San Diego, Calif.) raised $134 million led by CEO Hiroshi Mikitani in the second tranche of a $284 million series C round as the company conducts a Phase III trial of photoimmunotherapy...
20:19 , Nov 27, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Mouse studies identified a bispecific mAb against EGFR and 4-1BB that could help treat colorectal cancer. The bispecific, trimeric mAb consisted of an anti-human EGFR single-domain antibody linked to the C-terminus of...
19:54 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

Keytruda monotherapy improves survival by 39% in PD-L1-positive SCCHN patients

Merck & Co. Inc. (NYSE:MRK) reported detailed data from the Phase III KEYNOTE-048 trial to treat recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) showing that first-line treatment with Keytruda pembrolizumab...
19:01 , Oct 26, 2018 |  BC Week In Review  |  Company News

AstraZeneca gets rights, options to Innate immuno-oncology therapies

AstraZeneca plc (LSE:AZN; NYSE:AZN) expanded its next generation immuno-oncology pipeline on Oct. 23, gaining rights and options to a basket of therapies from Innate Pharma S.A. (Euronext:IPH). In return, Innate gained U.S. and European commercialization...
17:59 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Roche reports responses for IL-2 variant at ESMO

A targeted IL-2 variant from Roche (SIX:ROG; OTCQX:RHHBY) showed monotherapy activity in patients with metastatic solid tumors in a Phase I trial. Data presented at the European Society for Medical Oncology in Munich from the...